A Phase 1 interventional study of Rivaroxaban (BAY 59-7939) and Rivaroxaban (Xarelto, BAY 59-7939) in Embolism, Atrial Fibrillation and Venous Thrombosis, sponsored by Bayer. Completed at 1 site in Japan. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-09-01.
Sponsored by Bayer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Embolism by Bayer — none open to participants now, none under way, none of them phase 3. Embolism · Bayer.
Among the 11 studies in Embolism by Bayer, this one is one of 2 that started in 2014, is one of 3 in phase 1, and was the 8th registered.
104 studies on the registry are indexed under Embolism; 14 are open to participants now.
Browse Embolism studies →None of the 11 studies in Embolism by Bayer is open now. The open studies under Embolism, anywhere →
Of the 9 Embolism studies recruiting now, 7 set no upper age limit and none stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 20 Years to 40 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 150 across 61 interventional studies indexed under Embolism.
Median enrollment 40 across the 5 interventional studies, 2,199 across the 6 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Embolism by Bayer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objectives of this study are to establish the bioequivalence between rivaroxaban tablet 10mg and rivaroxaban granule formulation 10mg, and to assess the safety and tolerability of rivaroxaban 10mg in healthy adult male subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Rivaroxaban (BAY 59-7939)
Drug: Rivaroxaban (Xarelto, BAY 59-7939)
Rivaroxaban granule 10mg for one day
Rivaroxaban tablet 10mg for one day
Cmax (maximum observed drug concentration in measured matrix after single dose administration)
Time frame: Multiple time point up to 3 day
AUC(0-tlast) (AUC from time 0 to the last data point > LLOQ (lower limit of quantitation))
Time frame: Multiple time point up to 3 day
Number of participants with adverse events as a measure of safety and tolerability
Time frame: Up to 30 day
The record gives a start of Feb 2014, a primary completion of Mar 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban